Amylin as a Future Obesity Treatment
Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment. Amylin is co-secreted with insulin from β pancreati...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society for the Study of Obesity
2021-12-01
|
| Series: | Journal of Obesity & Metabolic Syndrome |
| Subjects: | |
| Online Access: | http://journaleditor.inforang.com/journal/view.html?doi=10.7570/jomes21071 |
| _version_ | 1819283388160278528 |
|---|---|
| author | Babak Dehestani Nicholas RS Stratford Carel W le Roux |
| author_facet | Babak Dehestani Nicholas RS Stratford Carel W le Roux |
| author_sort | Babak Dehestani |
| collection | DOAJ |
| description | Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment. Amylin is co-secreted with insulin from β pancreatic cells upon nutrient delivery to the small intestine as a satiety signal, acts upon sub-cortical homeostatic and hedonic brain regions, slows gastric emptying, and suppresses post-prandial glucagon responses to meals. Therefore, new pharmacological amylin analogues can be used as potential anti-obesity medications in individuals who are overweight or obese. In this narrative review, we analyse the efficacy, potency, and safety of amylin analogues. The synthetic amylin analogue pramlintide is an approved treatment for diabetes mellitus which promotes better glycaemic control and small but significant weight loss. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor. This calcitonin G protein-coupled receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of food intake and significant weight loss in a dose-dependent manner. |
| first_indexed | 2024-12-24T01:30:41Z |
| format | Article |
| id | doaj.art-088c4d1b3e7d4ce99fafb419e709360e |
| institution | Directory Open Access Journal |
| issn | 2508-6235 |
| language | English |
| last_indexed | 2024-12-24T01:30:41Z |
| publishDate | 2021-12-01 |
| publisher | Korean Society for the Study of Obesity |
| record_format | Article |
| series | Journal of Obesity & Metabolic Syndrome |
| spelling | doaj.art-088c4d1b3e7d4ce99fafb419e709360e2022-12-21T17:22:22ZengKorean Society for the Study of ObesityJournal of Obesity & Metabolic Syndrome2508-62352021-12-0130432032510.7570/jomes21071jomes21071Amylin as a Future Obesity TreatmentBabak Dehestani0Nicholas RS Stratford1Carel W le Roux2Department of Metabolic Medicine, Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Dublin, IrelandDepartment of Metabolic Medicine, Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Dublin, IrelandDepartment of Metabolic Medicine, Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Dublin, IrelandObesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment. Amylin is co-secreted with insulin from β pancreatic cells upon nutrient delivery to the small intestine as a satiety signal, acts upon sub-cortical homeostatic and hedonic brain regions, slows gastric emptying, and suppresses post-prandial glucagon responses to meals. Therefore, new pharmacological amylin analogues can be used as potential anti-obesity medications in individuals who are overweight or obese. In this narrative review, we analyse the efficacy, potency, and safety of amylin analogues. The synthetic amylin analogue pramlintide is an approved treatment for diabetes mellitus which promotes better glycaemic control and small but significant weight loss. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor. This calcitonin G protein-coupled receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of food intake and significant weight loss in a dose-dependent manner.http://journaleditor.inforang.com/journal/view.html?doi=10.7570/jomes21071obesitytreatmentsatietyanalogueweight loss |
| spellingShingle | Babak Dehestani Nicholas RS Stratford Carel W le Roux Amylin as a Future Obesity Treatment Journal of Obesity & Metabolic Syndrome obesity treatment satiety analogue weight loss |
| title | Amylin as a Future Obesity Treatment |
| title_full | Amylin as a Future Obesity Treatment |
| title_fullStr | Amylin as a Future Obesity Treatment |
| title_full_unstemmed | Amylin as a Future Obesity Treatment |
| title_short | Amylin as a Future Obesity Treatment |
| title_sort | amylin as a future obesity treatment |
| topic | obesity treatment satiety analogue weight loss |
| url | http://journaleditor.inforang.com/journal/view.html?doi=10.7570/jomes21071 |
| work_keys_str_mv | AT babakdehestani amylinasafutureobesitytreatment AT nicholasrsstratford amylinasafutureobesitytreatment AT carelwleroux amylinasafutureobesitytreatment |